Information letter to healthcare professionals on the medicinal product Plaquenil® (hydroxychloroquine): potential risk of serious congenital malformations and new risks

09.12.2024 815 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо лікарського засобу Плаквеніл®(гідроксихлорохін): потенційного ризику серйозних вроджених вад розвитку й нових ризиківPDF · 187 КБ

Завантажити

Information letter to healthcare professionals on the medicinal product Plaquenil® (hydroxychloroquine): potential risk of serious congenital malformations and new risks

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to healthcare professionals on the medicinal product Plaquenil® (hydroxychloroquine): potential risk of serious congenital malformations and new risks

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration